Epizyme (NASDAQ: [[ticker:EPZM]]) said that its longtime president of research and chief scientific officer, Robert Copeland, will retire in the second quarter to “pursue advisory and other opportunities within the industry,” the company said in a statement. Copeland has been at Epizyme since 2008 and will remain a “key advisor” to the company after he … Continue reading “Epizyme Research Chief, Copeland, to Retire”
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
Report: Biogen Tech Exec Karaboutis Leaves After Two-Plus Years
Adriana Karaboutis, Biogen’s (NASDAQ: [[ticker:BIIB]]) executive vice president of technology, business solutions, and corporate affairs, has left the company, according to the Wall Street Journal. Karaboutis, a former Dell and General Motors executive, was hired by Biogen in late 2014.
Biotech Vet Dunsire’s New Challenge: Grow Tiny Startup, XTuit
Boston biotech veteran Deborah Dunsire is back running another life sciences company—but for the first time, a fledgling startup. The former head of Millennium Pharmaceuticals is now president and CEO of a two-year-old company called XTuit Pharmaceuticals. XTuit is a very different animal from the companies Dunsire (pictured) has helped lead in the past. She … Continue reading “Biotech Vet Dunsire’s New Challenge: Grow Tiny Startup, XTuit”
Vertex Bags Concert’s Rival CF Drug For $160M, Plans Combo Studies
Concert Pharmaceuticals has been plugging away with an experimental cystic fibrosis drug that, if successful, might someday pose a threat to Vertex Pharmaceuticals. So rather than wait to find out, Vertex today paid $160 million in cash, up front, to bring the drug in house. Boston-based Vertex (NASDAQ: [[tickerVRTX]]) has acquired CTP-656, a CF drug … Continue reading “Vertex Bags Concert’s Rival CF Drug For $160M, Plans Combo Studies”
No Details Yet, But Genentech Drug Combo Wins in Big Breast Cancer Study
There may be a new standard of care coming for a large portion of women with breast cancer who have had surgery to remove their tumors. A drug from Roche’s South San Francisco, CA, Genentech unit, known as pertuzumab (Perjeta), has helped reduce the risk of death for such women when given in combination with … Continue reading “No Details Yet, But Genentech Drug Combo Wins in Big Breast Cancer Study”
Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M
Last month, Grail publicly spread word of intentions to raise more than $1 billion in an ambitious quest to develop a blood test that can diagnose and detect cancer at its earliest stages. Today, the Menlo Park, CA, startup has revealed the crop of drugmakers and others it has secured to fund the effort. Grail … Continue reading “Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M”
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment
Two newly approved drugs slow the progression of the rare and deadly Duchenne muscular dystrophy, but nothing on the market actually reverses the march of the disease. An emerging group of experimental gene therapy and gene editing treatments designed to do so are creeping towards human clinical testing, however, and one of them has just … Continue reading “Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment”
At Arrakis, Gilman Teams With Biogen Vets to Target RNA With Pills
A year after selling his latest biotech startup—the second since 2012—Michael Gilman is back. He emerged today as chairman and CEO of a two-year-old startup named Arrakis Therapeutics, which aims to use chemical drugs to go after an unlikely target: RNA, the molecules that turn our genetic blueprints into proteins. Named after the dangerous desert … Continue reading “At Arrakis, Gilman Teams With Biogen Vets to Target RNA With Pills”
Celgene Promotes Smith to President, Fouse to Retire
Summit, NJ-based Celgene (NASDAQ: [[ticker:CELG]]) said that president and chief operating officer Jacqualyn Fouse will retire and be replaced by Scott Smith, who currently runs the company’s inflammation and immunology franchise. Smith will take on his new role on April 1, when Fouse will transition to being a strategic adviser. She will officially retire from … Continue reading “Celgene Promotes Smith to President, Fouse to Retire”
Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO
Harvard University chemical biologist Greg Verdine has been learning how to start and run biotech companies for almost two decades. He’s been a scientific co-founder of ten startups, worked at three different healthcare-focused venture capital firms, and even run a few biotechs in their early days before handing them off to more seasoned life sciences … Continue reading “Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO”
Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M
PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company, headquartered in Cranbury, NJ, disclosed this morning that it has raised a $74 million Series B round from Topspin Biotech … Continue reading “Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M”
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M
Sarepta Therapeutics didn’t just get its first drug to market when the FDA approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) last year—it got a potentially lucrative voucher from the FDA too. Today the Cambridge, MA, company cashed that in. Sarepta (NASDAQ: [[ticker:SRPT]]) this morning sold what’s known as a priority review voucher to … Continue reading “Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M”
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More
News may be coming out of Washington, DC, at a breakneck pace, but concrete plans regarding the future of the nation’s healthcare system, the FDA, and the pharmaceutical industry have been much slower to materialize. The consternation about President Donald Trump’s coming pick for FDA commissioner was palpable this week at the BIO CEO & … Continue reading “Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More”
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision?
Perhaps this year, Spark Therapeutics could be the first ever in the U.S. to win approval of a gene therapy with its one-time treatment for an inherited form of blindness. But an approval could also throw Spark into the line of fire in the U.S. fight over drug pricing that includes angry members of Congress, … Continue reading “His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision?”
FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs
In three years, investment has jumped more than twenty-fold in startups developing medicines that change the interactions between our bodies and the bacteria that colonize it, known collectively as the human microbiome. But as a panel of industry insiders noted yesterday at the BIO CEO & Investor Conference Monday, the field faces several challenges—including lack … Continue reading “FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs”
Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs
Just how open is the IPO window for biotechs in 2017? After a solid start this year for life sciences offerings, two companies haven’t been able to get to market—the latest being Cambridge, MA-based Visterra. According to IPO research firm Renaissance Capital, Visterra has postponed an IPO that was supposed to net the firm $50 … Continue reading “Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs”
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data
Acorda Therapeutics took a calculated risk in 2014 when it bought Civitas Therapeutics in a bid to start accumulating drugs for Parkinson’s disease. But that deal has a chance to soon pay off for the Ardsley, NY, company. Acorda (NASDAQ: [[ticker:ACOR]]) said that CVT-301, its experimental Parkinson’s drug, succeeded in a 339-patient Phase 3 trial. … Continue reading “Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data”
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban
The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing “deep concern and opposition” to the order, which bars entry to the U.S. to refugees and immigrants from seven Muslim-majority countries. The Jan. 27 order placed … Continue reading “Biotech Leaders Sign Letter Condemning Trump’s Travel Ban”
Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins
Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life sciences. Many in biopharma blasted Trump’s order and tried to grapple with its implications. At the same time, a handful of the … Continue reading “Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins”
No Details Yet, But Amgen Touts Success in Big Heart Drug Study
Amgen revealed on Thursday that its cholesterol lowering drug, evolocumab (Repatha)—part of a new class of heart treatments called PCSK9 inhibitors—has reduced the risk of heart attacks and strokes in a massive, 27,500 patient trial. Thousand Oaks, CA-based Amgen (NASDAQ: [[ticker:AMGN]]) didn’t disclose the actual magnitude of the benefit evolocumab produced in the study, an … Continue reading “No Details Yet, But Amgen Touts Success in Big Heart Drug Study”
Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof
[Updated, 1:57 pm E.T., see below] Another major U.S. health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely watched bellwether in the national debate over drug prices. While UHC’s policy is less restrictive than the one disclosed recently by rival insurer Anthem, UHC … Continue reading “Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof”
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths
Biogen, one of the largest biotechnology companies in the world, was at a crossroads in 2016. An experimental drug for the memory-robbing scourge, Alzheimer’s disease, had shown signs of promise. That meant long, expensive, and risky Phase 3 trials lay ahead for Biogen to see if the early signals were more than a mirage. So … Continue reading “Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths”
Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy
Despite the early and in some cases stunning results produced by gene therapy treatments in handfuls of hemophilia patients, significant questions remain about their durability, safety, and how broadly they’ll be used if they are ultimately shown to work. The first human data produced by Dimension Therapeutics, one of several companies developing hemophilia gene therapies, … Continue reading “Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy”
FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits
The race to treat kidney disease patients’ anemia with a pill, rather than an injectable biologic, continues. FibroGen this morning announced positive interim results from two Phase 3 trials that could support the first approval application for its anemia pill, roxadustat, in China. But longer studies that could prove how safe the drug is are … Continue reading “FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits”
Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More
It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender parity in public biotech boardrooms. Tensions continued to mount between drugmakers and payers over the rising costs of rare disease drugs. A flurry of deals took place, headlined by Johnson & … Continue reading “Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More”
Jounce Gets $102M As Biotech IPOs Gain Steam in ’17
Jounce Therapeutics has gone ahead of its projections and raised roughly $102 million in an IPO, continuing an early, yet successful trend for biotechs trying to go public in 2017. The Cambridge, MA, company sold close to 6,365,000 shares at $16 apiece, almost 1 million more shares than it proposed to sell a few weeks … Continue reading “Jounce Gets $102M As Biotech IPOs Gain Steam in ’17”
Just Four Months After Series A, Delinia Sells to Celgene For $300M
It didn’t take long for startup Delinia to entice a big drug developer: Just over four months after emerging from stealth and raising a Series A round, the company, developing drugs for a range of autoimmune diseases, has been acquired by Celgene. Celgene (NASDAQ: [[ticker:CELG]]) will pay $300 million up front to buy Cambridge, MA-based … Continue reading “Just Four Months After Series A, Delinia Sells to Celgene For $300M”
Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval
One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of the drug, nusinersen (Spinraza), might make it hard for some with the disease to get treatment. Indianapolis-based Anthem (NYSE: [[ticker:ANTM]]) has disclosed its … Continue reading “Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval”
With Another Migraine Drug Bet, Lilly Snaps Up CoLucid For $960M
Eli Lilly may have dealt a migraine drug called lasmiditan to CoLucid Pharmaceuticals 12 years ago, but the Indianapolis giant has clearly kept an eye on it, and now wants more than just some royalties if the treatment succeeds in clinical testing this year. Lilly (NYSE: [[ticker:LLY]]) will acquire Cambridge, MA-based CoLucid (NASDAQ: [[ticker:CLCD]]) in an … Continue reading “With Another Migraine Drug Bet, Lilly Snaps Up CoLucid For $960M”
Merrimack Names Sanofi/Genzyme Exec, Peters, New CEO
Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]) has named Richard Peters its new president and CEO, stepping in for chairman Gary Crocker, who had manned the seat while the Cambridge, MA, company restructured. Peters is currently the senior vice president and head of Sanofi/Genzyme’s rare disease business, but has served in some oncology roles—Merrimack’s focus— at Sanofi/Genzyme as … Continue reading “Merrimack Names Sanofi/Genzyme Exec, Peters, New CEO”
Hunting For Pharma Deals, Ovid Bags Epilepsy Drug from Takeda
Big pharmaceutical companies are always on the hunt for promising drugs from smaller biotechs. But the reverse is true, too, and that can lead to creative deals such as the arrangement between New York startup Ovid Therapeutics and Japanese pharma giant Takeda announced this morning. Ovid, formed in 2015 by ex-Teva Pharmaceutical and Bristol-Myers Squibb … Continue reading “Hunting For Pharma Deals, Ovid Bags Epilepsy Drug from Takeda”
Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More
[Corrected, 1/14/16, see below] This past week, the biopharma industry made its annual January pilgrimage to San Francisco for the J.P. Morgan Healthcare Conference. 2016 was a whirlwind year in biotech, and the biopharma gods rewarded attendees with a multi-day monsoon to slog through to get from one meeting to the next. Earlier today, Alex … Continue reading “Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More”
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug
Sarepta Therapeutics CEO Ed Kaye described Tuesday the ups and downs the Cambridge, MA, company has had as it tries to roll out eteplirsen (Exondys 51), the first-ever approved drug for Duchenne muscular dystrophy. At the JP Morgan Healthcare Conference in San Francisco, Kaye told attendees that more than 250 patients with the progressive, deadly … Continue reading “CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug”
J&J, NY State to Form Biotech Incubator in Big Apple’s Genome Center
New York State Governor Andrew Cuomo is planning to use some of the cash from his recently announced $650 million biotech initiative on Manhattan’s biggest life sciences problem—lack of lab space. Cuomo will put $17 million in state funding towards a new biotech startup incubator that will be situated in the New York Genome Center … Continue reading “J&J, NY State to Form Biotech Incubator in Big Apple’s Genome Center”
Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M
Merrimack Pharmaceuticals is starting off the year with significant changes. The Cambridge, MA, company has decided to sell its only marketed products—a pair of cancer drugs—to pay off debt and invest in a new set of experimental medicines. French pharmaceutical company Ipsen has bought Merrimack’s rights to the nanoparticle pancreatic cancer drug Onivyde and its … Continue reading “Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M”
Foundation, Roche Deepen Ties as Genentech Vet Steps in for CEO Pellini
[Updated, 2:37 pm ET] Two years ago, almost to the day, Foundation Medicine celebrated its biggest announcement ever. Roche had just paid more than $1 billion for a majority stake in the cancer diagnostics company in a sweeping collaboration that sent Foundation’s shares to all-time highs. Fast forward to today, and Cambridge, MA-based Foundation (NASDAQ: … Continue reading “Foundation, Roche Deepen Ties as Genentech Vet Steps in for CEO Pellini”
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug
This past Christmas weekend, Ana Memedovich had her best two days in more than a decade. Her 23-year-old son Mikhail has spinal muscular atrophy, or SMA, a rare genetic disease that has slowly robbed him of the ability to walk and function independently. On Dec. 23, the FDA approved nusinersen (Spinraza), the first-ever drug for … Continue reading “Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug”
Infinity Pharma R&D Chief Adams Retires Amid Restructuring, Job Cuts
Julian Adams, renowned for inventing bortezomib (Velcade), a drug that revolutionized multiple myeloma treatment years ago, is retiring from his role as president of research and development at Cambridge, MA-based Infinity Pharmaceuticals (NASDAQ: [[ticker:INFI]]). Adams (pictured above, right) has worked at Infinity since 2003 and will step down this week amid a sweeping restructuring at … Continue reading “Infinity Pharma R&D Chief Adams Retires Amid Restructuring, Job Cuts”
Alnylam Promotes Garg to CMO, CBO Gros Heads to West Coast
David-Alexandre Gros will resign from his post as the senior vice president and chief business officer of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) for personal reasons, to “return to the West Coast in a broader operating role,” according to a statement. Alnylam will also promote head of clinical development Pushkal Garg to chief medical officer. … Continue reading “Alnylam Promotes Garg to CMO, CBO Gros Heads to West Coast”
RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal
RaNA Therapeutics is branching out. Today, the Cambridge, MA, startup is acquiring some assets from pharmaceutical giant Shire that immediately make it a player in an emerging, yet unproven field of drugmaking—messenger RNA therapeutics. Cambridge, MA-based RaNA has acquired a small, recently shuttered unit of Shire (NASDAQ: [[ticker:SHPG]]) devoted to making drugs with synthetic mRNA. … Continue reading “RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal”
Inotek’s Glaucoma Drug Flunks in First Phase 3 Test, Shares Crumble
Inotek Pharmaceuticals has started 2017 with a big setback. The company’s first big Phase 3 test of an experimental glaucoma drug fell far short this morning, leaving the fate of the drug, known as trabodenoson, unclear. Lexington, MA-based Inotek (NASDAQ: [[ticker:ITEK]]) said that trabodenoson failed MATrX-1, the first of three Phase 3 trials in glaucoma … Continue reading “Inotek’s Glaucoma Drug Flunks in First Phase 3 Test, Shares Crumble”
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work
Even though Jounce Therapeutics has no human clinical data to report yet, a partnership with Celgene and support from a broad group of investors have made the Cambridge, MA, cancer drug developer a likely IPO candidate for some time now. Jounce made those intentions clear Friday, filing papers to try for an IPO that would … Continue reading “First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work”
Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech
The idea that New York City could become a biotech powerhouse dates back to the late 1990s. It’s been a slow, tedious process, and it’s nowhere near complete, but from near and far, Harold Varmus and Vicki Sato have been watching the gears begin to turn. Varmus, who earned a Nobel prize for his work … Continue reading “Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech”
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug
[Updated, 12/29/16, see below] Patients with spinal muscular atrophy got some good news last week when the FDA approved nusinersen (Spinraza), making it the first marketed drug ever for the rare and potentially deadly genetic disease. But as expected, the drug, from Biogen and Ionis Pharmaceuticals, is a costly one, priced at the high end … Continue reading “Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug”
Ionis, Biogen Make History With FDA Nod for Spine Disease Drug
Patients with spinal muscular atrophy got an early Christmas present on Friday. The FDA approved nusinersen (Spinraza), making the drug the first-ever marketed treatment for the rare, potentially deadly genetic disorder. Nusinersen is an injectable drug developed by Ionis Pharmaceuticals (NASDAQ: [[ticker:IONS]]) and partner Biogen (NASDAQ: [[ticker:BIIB]]), and is meant to slow the progression of … Continue reading “Ionis, Biogen Make History With FDA Nod for Spine Disease Drug”
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)
[Updated, 4:28 pm ET, see below] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company. There were high profile successes in 2016. Biogen (NASDAQ: [[ticker:BIIB]]) and Ionis Pharmaceuticals (NASDAQ: … Continue reading “14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)”
Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push
Akebia Therapeutics is in a high-stakes race with rival Fibrogen to treat anemia with a pill, not an injectable biologic. And it just got a bunch of cash to try to get to the clinical finish line. In a deal announced this morning, Japan’s Otsuka Pharmaceutical will commit $265 million to Cambridge, MA-based Akebia (NASDAQ: … Continue reading “Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push”
Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug
Slowly but surely, a new group of drugs known as “PARP” inhibitors are starting to become fixtures in the regimens for women with ovarian cancer—and perhaps more. With the approval of a drug called rucaparib (Rubraca) from Clovis Oncology, two have now been approved since 2014—and a third, from Waltham, MA-based Tesaro (NASDAQ: [[ticker:TSRO]]), could … Continue reading “Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug”
Creating Bio “Gestalt” And Photos From New York Life Sciences 2021
New York City Deputy Mayor Alicia Glen said it best: “It’s about creating what I call a ‘New York gestalt’ around life sciences.” Showing that New York biotech can rise above its problems, become greater than the sum of its currently disparate parts, and create a brand that ranks up there with Wall Street, the … Continue reading “Creating Bio “Gestalt” And Photos From New York Life Sciences 2021”
After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies
Ophthotech’s attempt to change the standard of care for a common form of vision loss, age related macular degeneration, fell short earlier this week, sending shares spiraling downward and leaving the fate of the company and its lead drug, pegpleranib (Fovista), unclear. The company clarified two things today—its future will involve a much smaller workforce, … Continue reading “After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies”